EVEREST ORGANICS LTD. Share Price

BSE: 524790

S Cap

₹ 267.00

-₹10.00 (-3.61%)

Last updated 02 Sep, 2026, 15:29 IST

EVEREST ORGANICS LTD. Share Price Today

As of 3 Sep 2026, EVEREST ORGANICS LTD. share price is ₹267.00. The stock opened at ₹273.05, compared to its previous close of ₹277.00. During today's trading session, EVEREST ORGANICS LTD. share price moved in the range of ₹265.05 to ₹275.00, with an average price of ₹270.02 for the day. Looking at its last 52-week, the stock has touched a low of ₹197.00 and a high of ₹536.40.

₹265.05

3.61% down today

₹275.00

1D LOW

1D HIGH

Stock Performance

OutperformingBeat Nifty by 5.33 % in last 3 month

Shareholding Pattern

PromoterPromoter increased stake by 0.04%

EVEREST ORGANICS LTD. Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹3,39,154-₹1,60,846 (-32.17%)

3 Year

₹11,21,117+₹6,21,117 (+124.22%)

5 Year

₹4,43,310-₹56,690 (-11.34%)

₹213.65₹320.45

Circuit Low

Circuit High

₹197.00₹536.40

52-Week Low

52-Week High

Circuit

₹213.65

₹320.45

52-week

₹197.00

₹536.40

About EVEREST ORGANICS LTD.

ISIN

INE334C01029

Sector Market Cap

₹ 266.35 Cr

Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.

EVEREST ORGANICS LTD. Financial Highlights

Revenue: EVEREST ORGANICS LTD. reported revenue of ₹197.41 crore in FY26 vs ₹160.17 crore in FY25. It showed an increase of 23.25% on a yearly basis.
Operating Profit: EVEREST ORGANICS LTD. reported an operating profit of ₹8.05 crore in FY26 vs ₹3.24 crore in FY25. It showed an increase of 348.46% on a year-on-year basis.
Net Profit: EVEREST ORGANICS LTD. reported a net profit of ₹5.55 crore in FY26 vs ₹1.29 crore in FY25. It showed an increase of 530.23% on a yearly basis.

EVEREST ORGANICS LTD. Quarterly Result Highlights

EVEREST ORGANICS LTD. reported revenue of ₹48.85 crore in Jun 2026, compared with ₹48.91 crore in Mar 2026, representing a decrease of 0.12% on a quarter-on-quarter (QoQ) basis.
EVEREST ORGANICS LTD. reported an operating profit of ₹1.53 crore in Jun 2026, compared with ₹2.17 crore in Mar 2026, representing a decrease of 29.49% on a quarter-on-quarter (QoQ) basis.
EVEREST ORGANICS LTD. reported a profit of ₹1.11 crore in Jun 2026, compared with ₹2.63 crore in Mar 2026, reflecting a decrease of 57.79% on a QoQ basis.
The earnings per share (EPS) of EVEREST ORGANICS LTD. stood at ₹2.97 during Jun 2026.

Know more

Promoters

59.60%

FII

0.00%

Other DII

0.02%

Retail and other

40.37%

Mutual funds

0.00%

Foreign institutions - FII

FII shareholding by period
Sep 2025	0.00%
Dec 2025	0.00%
Mar 2026	0.00%
Jun 2026	0.00%

Mkt Cap Cr

266.35

P/E

50.67

P/B

3.35

ROE

7.35%

D/E

0.66

ROCE

11.62%

Div. Yield

0.00%

EPS(TTM)

5.70

Turnover

0.80

EV/EBITDA

15.64

Net Margin

0.00%

Op. Margin

0.00%

ROA

2.19%

Quick Ratio

0.00

Curr. Ratio

1.53

Mkt Cap Cr

266.35

P/E

50.67

P/B

3.35

ROE

7.35%

D/E

0.66

ROCE

11.62%

Div. Yield

0.00%

EPS(TTM)

5.70

Turnover

0.80

EV/EBITDA

15.64

Net Margin

0.00%

Op. Margin

0.00%

ROA

2.19%

Quick Ratio

0.00

Curr. Ratio

1.53

Based on fundamentals, this stock's

Performance

Very Poor

Everest Organics has not beaten FD return of 7%

Valuation

Overvalued

Everest Organics appears overvalued compared to its peers

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,63,180.00	38.28	5.55	13.74%	0.61	17.33%	93.24	0.83%	0.48	10.90
Divis Laboratories	2,43,302.00	83.79	14.62	15.32%	0.00	19.56%	629.49	0.32%	0.55	98.19
Torrent Pharmaceuticals	1,88,623.00	88.29	22.64	25.49%	1.69	13.85%	222.76	0.68%	0.49	58.70
Zydus Lifesciences	1,16,114.00	25.00	4.24	18.59%	0.31	17.35%	237.30	0.09%	0.33	35.38
Cipla	1,14,554.00	34.02	3.32	11.27%	0.00	14.95%	423.36	0.92%	0.45	43.52
Laurus Labs	1,00,660.00	92.32	18.99	16.77%	0.40	16.14%	97.20	0.11%	0.67	13.72
Lupin	98,312.20	17.73	4.38	23.76%	0.04	24.88%	659.00	0.84%	0.57	129.18
Dr. Reddy's Laboratories	96,906.30	30.44	2.55	11.07%	0.18	12.54%	377.95	0.69%	0.41	38.68
Mankind Pharma	97,467.00	47.54	6.03	11.74%	0.34	13.13%	397.02	0.04%	0.44	49.37
Aurobindo Pharma	96,836.10	25.68	2.52	9.25%	0.19	11.76%	394.82	0.24%	0.38	41.58

EVEREST ORGANICS LTD. Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹159.48	₹197.24	₹183.05	₹200.05
Other Income	₹0.69	₹0.89	₹6.94	₹2.21
Total Revenue	₹160.17	₹198.13	₹189.99	₹202.26
Total Expenses	₹163.41	₹197.52	₹189.90	₹200.52
Profit Before Tax	-₹3.24	₹0.61	₹0.09	₹1.74
Tax	-₹1.95	₹0.47	₹0.27	₹0.60
Profit After Tax	-₹1.29	₹0.14	-₹0.18	₹1.14
EPS - Basic	-₹2.97	₹0.17	-₹0.23	₹1.43
EPS - Diluted	-₹2.97	₹0.17	-₹0.23	₹1.43

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	-₹3.24	₹0.14	-₹0.18	₹1.14
Income before WC changes	₹7.04	₹10.79	₹7.57	₹7.87
Change in Assets	₹6.23	-₹17.50	-₹14.43	-₹29.64
Change in Liabilities	-₹18.76	₹23.13	₹25.28	₹35.51
Change in WC	-₹12.53	₹5.63	₹10.85	₹5.87
Cash flow from Operations	-₹5.38	₹16.42	₹18.42	₹13.74
Cash flow from Investing	-₹5.17	-₹13.32	-₹15.60	-₹16.82
Cash flow from Financing	₹16.36	-₹3.10	-₹2.65	₹2.07
Total Cash Flow	₹5.82	₹0.00	₹0.18	-₹1.01
Cash (Start of the year)	₹0.27	₹0.27	₹0.65	₹1.66
Cash (End of the year)	₹6.09	₹0.27	₹0.83	₹0.65

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹76.58	₹76.74	₹69.37	₹60.12
Current Assets	₹147.90	₹149.98	₹132.48	₹117.88
Total Assets	₹224.48	₹226.72	₹201.85	₹178.00
Current Liabilities	₹139.92	₹160.10	₹137.58	₹112.56
Net Current Asset	₹7.98	-₹10.12	-₹5.10	₹5.32
Non-Current Liabilities	₹14.61	₹20.78	₹18.05	₹18.64
Equity Capital	₹69.95	₹45.84	₹46.21	₹46.80
Total Equity & Liabilities	₹224.48	₹226.72	₹201.85	₹178.00